Dasatinib
Kinase inhibitor: tyrosine kinases. Inhibits SARS-CoV and MERS-CoV in cells. Dyall et al. Antimicrob. Agents Chemother., 58:4885-4893 2014, https://doi.org/10.1128/aac.03036-14; Laise et al. bioRxiv, May 17 2020, https://doi.org/10.1101/2020.05.12.091256.
- Datasheet: view or download
- Applications:Approved drug (U.S.) that could be repurposed
Biochemicals & reagents
302962-49-8
1) Lombardo et al. (2004), Discovery of N-2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a duel Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays; J. Med. Chem., 47 6658 2) Nam et al. (2005), Action of the Src family kinase inhibitor dasatinib (BMS-354825), on human prostate cancer cells; Cancer Res., 65 9185 3) Johnson et al. (2005), Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells; Clin. Cancer Res., 11 6924
488.01
-20°C (des.)
Dasatinib inhibits Src, Bcl/Abl and Lyn tyrosine kinases with IC50 = 0.55, 3.0 and 8.5 nM respectively (1,2). This compound suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells (3).